Key facts
- It has raised $520K across 1 recorded rounds; the latest was Seed Round ($519K) in May 2025.
- Mizar Therapeutics has filed 1 Form D with the SEC, most recently Jun 2025 ($519K sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Mizar Therapeutics
Funding rounds
1 roundsAbout Mizar Therapeutics
Developer of therapeutics platform designed to use proprietary live-cell single-molecule imaging and machine-learning technology for the discovery of a new class of targeted cancer therapies. The company's platform offers live-cell super-resolution imaging, AI-powered data extraction, and live-cell super-resolution technology to determine the interaction of lead compounds and condensate components in intact cells, enabling doctors to identify effective condensate modulators to novel targeted cancer therapeutics.
- Sector
- Healthcare
- HQ
- Woods Hole, MA, United States
- Founded
- 2017
- Employees
- 4
- Website
- mizartx.com/
- Ownership
- Privately Held (backing)
Mizar Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mizar Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mizar Therapeutics in its N-PORT filings yet. We sweep new filings monthly.